| Date Filed | Type | Description |
| 10/12/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2023 |
8-K/A
| Quarterly results |
| 09/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/26/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
SC 13D
| BIOGEN INC. reports a 23.4% stake in REATA PHARMACEUTICALS, INC. |
| 08/07/2023 |
3
| BIOGEN INC. (See footnotes) has filed a Form 3 on REATA PHARMACEUTICALS INC |
| 07/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/28/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/25/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Izzar Rachid (Head of Global Product Strat.) has filed a Form 4 on BIOGEN INC.|
Txns:
| Paid exercise price by delivering 244 shares
@ $284.85, valued at
$69.5k
Exercised 504 restricted stock units
@ $0 |
|
| 07/05/2023 |
4
| Kramer Robin (Chief Accounting Officer) has filed a Form 4 on BIOGEN INC.|
Txns:
| Paid exercise price by delivering 122 shares
@ $284.85, valued at
$34.8k
Exercised 252 restricted stock units
@ $0 |
|
| 07/05/2023 |
4
| Singhal Priya (Head of Development) has filed a Form 4 on BIOGEN INC.|
Txns:
| Paid exercise price by delivering 153 shares
@ $284.85, valued at
$43.6k
Sold 81 shares
@ $282.87, valued at
$22.9k
Exercised 315 restricted stock units
@ $0 |
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/28/2023 |
4
| SHERWIN STEPHEN A (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 960 shares
@ $0 |
|
| 06/28/2023 |
4
| Rowinsky Eric K (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 960 shares
@ $0 |
|
| 06/28/2023 |
4
| Mantas Jesus B (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 960 shares
@ $0 |
|
| 06/28/2023 |
4
| LANGER SUSAN (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 960 shares
@ $0 |
|
| 06/28/2023 |
3
| LANGER SUSAN (Director) has filed a Form 3 on BIOGEN INC. |
| 06/28/2023 |
4
| HAWKINS WILLIAM A (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 960 shares
@ $0 |
|
| 06/28/2023 |
4
| Freire Maria C (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 960 shares
@ $0 |
|
| 06/28/2023 |
4
| DORSA CAROLINE (Director) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 1,580 shares
@ $0 |
|
| 06/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/13/2023 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 06/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/03/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
4
| Keeney Adam (Head of Corporate Development) has filed a Form 4 on BIOGEN INC.|
Txns:
| Granted 2,815 restricted stock units
@ $0 |
|
| 05/02/2023 |
4
| Gregory Ginger (EVP, Human Resources) has filed a Form 4 on BIOGEN INC.|
Txns:
| Sold 2,681 shares
@ $300, valued at
$804.3k
|
|
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|